Associate Professor Marion Mafham
Associate Professor, Heart Studies Group
- Associate Professor, Oxford Population Health, University of Oxford
- British Heart Foundation Centre for Research Excellence, Senior Transition Fellow
- Honorary Consultant Nephrologist, Oxford University Hospitals NHS Foundation Trust
Marion Mafham is an associate professor working in the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at Oxford Population Health. Her work aims to improve health by generating reliable randomised evidence about the effects of interventions to treat and prevent common causes of death and disability, focusing on diabetes, cardiovascular and kidney diseases. She pioneers new trial methods to design large-scale streamlined randomised trials that produce reliable answers, including the use of healthcare systems data in clinical trials and direct-to-participant designs. She is module lead for the University of Oxford's MSc in clinical trials and co-leads the clinical trials program for Health Data Research UK.
Her recent clinical trials work includes the mail-based ASCEND study in 15,480 participants with diabetes, the ongoing 15,000 participant ORION-4 study in cardiovascular disease and she co-leads the ASCEND PLUS trial of oral semaglutide in type 2 diabetes. She leads the data linkage team for the RECOVERY trial assessing potential hospital treatments for COVID-19. Her research also uses healthcare systems data to generate real time insights into the impact of COVID-19 on NHS care pathways.
She studied medicine at the University of Edinburgh (1992-1998) and completed an MD thesis at the CTSU (2003-2006). After completing her specialist training in Nephrology she returned to CTSU in 2013.
Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
Harper C. et al, (2023), Heart
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: firstname.lastname@example.org None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial.
Parish S. et al, (2023), Trials, 24
Data provenance and integrity of health-care systems data for clinical trials.
Murray ML. et al, (2022), Lancet Digit Health, 4, e567 - e568
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368